Stockscreener 앱 받기
203.71
2.24%
-4.67
시간 외 거래:
204.35
0.64
+0.31%
전일 마감가:
$208.38
열려 있는:
$207.94
하루 거래량:
5.77M
Relative Volume:
0.82
시가총액:
$360.31B
수익:
$61.16B
순이익/손실:
$4.19B
주가수익비율:
86.27
EPS:
2.3614
순현금흐름:
$17.82B
1주 성능:
-1.34%
1개월 성능:
-0.66%
6개월 성능:
-12.22%
1년 성능:
+17.76%
1일 변동 폭
$202.84
$208.33
1주일 범위
$202.84
$212.35
52주 변동 폭
$168.54
$244.81
애브비 Stock (ABBV) Company Profile
명칭
Abbvie Inc
전화
(847) 932-7900
주소
1 NORTH WAUKEGAN ROAD, NORTH CHICAGO, IL
Compare ABBV vs LLY, JNJ, AZN, MRK
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ABBV
Abbvie Inc
|
203.71 | 368.57B | 61.16B | 4.19B | 17.82B | 2.3614 |
LLY
Lilly Eli Co
|
919.90 | 828.17B | 65.18B | 20.64B | 5.96B | 22.59 |
JNJ
Johnson Johnson
|
230.69 | 564.05B | 96.36B | 21.04B | 19.70B | 8.6488 |
AZN
Astrazeneca Plc
|
200.69 | 317.61B | 58.80B | 10.24B | 8.98B | 3.2788 |
MRK
Merck Co Inc
|
117.10 | 294.09B | 64.93B | 18.26B | 12.36B | 7.2751 |
애브비 Stock (ABBV) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-02-25 | 개시 | RBC Capital Mkts | Outperform |
| 2026-02-20 | 개시 | Barclays | Overweight |
| 2026-01-08 | 다운그레이드 | Wolfe Research | Outperform → Peer Perform |
| 2026-01-07 | 재개 | UBS | Neutral |
| 2025-12-10 | 업그레이드 | HSBC Securities | Hold → Buy |
| 2025-11-13 | 개시 | Scotiabank | Sector Outperform |
| 2025-11-04 | 다운그레이드 | DZ Bank | Buy → Hold |
| 2025-10-14 | 다운그레이드 | Erste Group | Buy → Hold |
| 2025-10-01 | 다운그레이드 | HSBC Securities | Buy → Hold |
| 2025-09-17 | 업그레이드 | Berenberg | Hold → Buy |
| 2025-08-12 | 재개 | Piper Sandler | Overweight |
| 2025-08-07 | 업그레이드 | Daiwa Securities | Neutral → Outperform |
| 2025-05-14 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2025-04-22 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-12-10 | 재개 | BofA Securities | Neutral |
| 2024-12-05 | 다운그레이드 | Daiwa Securities | Outperform → Neutral |
| 2024-11-22 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
| 2024-11-15 | 개시 | Wolfe Research | Outperform |
| 2024-11-04 | 업그레이드 | Argus | Hold → Buy |
| 2024-10-17 | 개시 | Bernstein | Mkt Perform |
| 2024-06-05 | 업그레이드 | HSBC Securities | Hold → Buy |
| 2024-05-17 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-01-29 | 업그레이드 | William Blair | Mkt Perform → Outperform |
| 2023-12-18 | 다운그레이드 | HSBC Securities | Buy → Hold |
| 2023-12-11 | 업그레이드 | Goldman | Neutral → Buy |
| 2023-11-09 | 개시 | Deutsche Bank | Hold |
| 2023-10-30 | 업그레이드 | Barclays | Equal Weight → Overweight |
| 2023-10-20 | 재개 | UBS | Neutral |
| 2023-09-29 | 개시 | Raymond James | Outperform |
| 2023-07-25 | 개시 | William Blair | Mkt Perform |
| 2023-07-14 | 개시 | HSBC Securities | Buy |
| 2023-04-05 | 다운그레이드 | Argus | Buy → Hold |
| 2023-03-01 | 개시 | Guggenheim | Buy |
| 2023-02-22 | 다운그레이드 | Wolfe Research | Outperform → Peer Perform |
| 2023-02-10 | 업그레이드 | SVB Securities | Underperform → Market Perform |
| 2022-11-18 | 개시 | Credit Suisse | Outperform |
| 2022-11-08 | 다운그레이드 | Societe Generale | Buy → Hold |
| 2022-08-01 | 다운그레이드 | Atlantic Equities | Overweight → Neutral |
| 2022-05-23 | 개시 | SVB Leerink | Underperform |
| 2022-05-06 | 다운그레이드 | Daiwa Securities | Outperform → Neutral |
| 2022-04-06 | 재개 | Morgan Stanley | Overweight |
| 2022-02-28 | 다운그레이드 | UBS | Buy → Neutral |
| 2022-02-03 | 재확인 | BMO Capital Markets | Outperform |
| 2022-02-03 | 재확인 | Barclays | Equal Weight |
| 2022-02-03 | 재확인 | BofA Securities | Neutral |
| 2022-02-03 | 재확인 | Goldman | Neutral |
| 2022-01-13 | 개시 | Redburn | Buy |
| 2022-01-12 | 재확인 | BMO Capital Markets | Outperform |
| 2021-12-09 | 재개 | Wells Fargo | Overweight |
| 2021-11-23 | 업그레이드 | Societe Generale | Hold → Buy |
| 2021-07-27 | 재개 | Truist | Buy |
| 2021-04-07 | 재개 | RBC Capital Mkts | Outperform |
| 2020-11-10 | 재개 | Bernstein | Outperform |
| 2020-09-29 | 개시 | Berenberg | Hold |
| 2020-06-23 | 업그레이드 | Atlantic Equities | Neutral → Overweight |
| 2020-06-09 | 업그레이드 | Wolfe Research | Peer Perform → Outperform |
| 2020-06-02 | 업그레이드 | Argus | Hold → Buy |
| 2020-05-18 | 재개 | BofA/Merrill | Neutral |
| 2020-05-12 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2020-05-11 | 재개 | Morgan Stanley | Overweight |
| 2020-04-20 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2020-03-23 | 다운그레이드 | Societe Generale | Buy → Hold |
| 2020-02-27 | 개시 | Barclays | Equal Weight |
| 2020-02-06 | 개시 | Mizuho | Buy |
| 2020-01-07 | 개시 | RBC Capital Mkts | Sector Perform |
| 2019-12-26 | 재확인 | Cowen | Outperform |
| 2019-09-26 | 업그레이드 | Citigroup | Neutral → Buy |
| 2019-08-20 | 업그레이드 | Piper Jaffray | Neutral → Overweight |
| 2019-06-27 | 업그레이드 | Wolfe Research | Underperform → Peer Perform |
| 2019-06-26 | 업그레이드 | SVB Leerink | Mkt Perform → Outperform |
| 2019-05-28 | 개시 | Goldman | Neutral |
| 2019-04-29 | 업그레이드 | BMO Capital Markets | Underperform → Market Perform |
모두보기
애브비 주식(ABBV)의 최신 뉴스
Biologics Market: Share and Outlook Driven by Roche, Amgen, and AbbVie Leading Advanced Therapeutics - openPR.com
Here's Why AbbVie (ABBV) Fell More Than Broader Market - Yahoo Finance
AbbVie and BioLabs Team Up to Support Life Sciences Innovation in Canada - Investing News Network
AbbVie Sponsors New BioLabs Facility in Toronto - marketscreener.com
Will AbbVie's Oncology Franchise Weigh on Q1 Top-line Growth? - qz.com
AbbVie And BioLabs Team Up To Support Life Sciences Innovation In Canada - TradingView
AbbVie and BioLabs Team Up to Support Life Sciences Innovation in Canada – Company Announcement - Financial Times
Nxera Pharma Co., Ltd. Reaches Third R&D Milestone Under Collaboration with Abbvie - marketscreener.com
Nxera to receive $10 million milestone from AbbVie deal - The Pharma Letter
AbbVie Makes $10 Million Milestone Payment to Nxera Pharma Under Collaboration - marketscreener.com
The Zacks Analyst Blog Microsoft, AbbVie, BHP, CBL & Associates Properties and IRIDEX - Zacks Investment Research
Top Dividend Stocks for Income: AbbVie & Enbridge Analysis | 2026 MarketNews and Statistics - IndexBox
Nxera Pharma to Receive US$10 Million Milestone Payment from AbbVie under Collaboration Targeting Neurological Diseases - GlobeNewswire Inc.
AbbVie (ABBV) Is One Of The Major Stock To Buy According To Wall Street - Insider Monkey
Lobbying Update: $180,000 of ABBVIE INC. lobbying was just disclosed - Quiver Quantitative
AbbVie Inc stock (US00287Y1091): Is its immunology dominance strong enough to unlock new upside? - AD HOC NEWS
ABBV Stock Quote Price and Forecast - CNN
Asset Management One Co. Ltd. Has $209.74 Million Stock Position in AbbVie Inc. $ABBV - MarketBeat
AbbVie Inc. (ABBV): A Bull Case Theory - MSN
AbbVie Inc. (NYSE:ABBV) Short Interest Update - MarketBeat
PBUThe Pension Fund of Early Childhood & Youth Educators's AbbVie Inc(ABBV) Holding History - GuruFocus
Top Analyst Reports for Microsoft, AbbVie & BHP - Yahoo Finance
Should you buy AbbVie stock before April 29? - MSN
AbbVie inks $745 million deal to develop pain medicines from Chinese drugmaker - Crain's Chicago Business
AbbVie Trades Below 50-Day and 200-Day SMA: How to Play the Stock - The Globe and Mail
AbbVie vs. Pfizer: One Pharma Dividend Has a Moat — The Other Is Praying for a Pipeline Hit - Yahoo Finance
DB&C Advisors, LLC's AbbVie Inc(ABBV) Holding History - GuruFocus
Merit Financial Group LLC Has $21.32 Million Stake in AbbVie Inc. $ABBV - MarketBeat
Pertzye Market Booming with Rapid Growth Through 2033| AbbVie • Nestlé Health Science • Solvay Pharmaceuticals - openPR.com
AE Wealth Management LLC Purchases 7,696 Shares of AbbVie Inc. $ABBV - MarketBeat
AbbVie, Inc. Trade Ideas — TURQUOISE:4ABD - TradingView
Portfolio Building Block World Pharma and Biotech Index ETF's AbbVie Inc(ABBV) Holding History - GuruFocus
Why AbbVie Is a No-Brainer Stock to Buy on the Dip - AOL.com
AbbVie Steps Deeper Into Obesity Market With New Phase 1 ABBV-295 Trial - TipRanks
AbbVie’s Head-to-Head Psoriasis Study Sets Up New Catalyst for ABBV Investors - TipRanks
ABBV: Abbott Laboratories Reports In-Line EPS and Strong Revenue Beat - GuruFocus
Analysts Offer Insights on Healthcare Companies: AbbVie (ABBV), McKesson (MCK) and Regeneron (REGN) - The Globe and Mail
Nations Financial Group Inc. IA ADV Has $4.88 Million Stock Position in AbbVie Inc. $ABBV - MarketBeat
Lbp Am Sa Purchases 8,678 Shares of AbbVie Inc. $ABBV - MarketBeat
AbbVie eases the pain with $745m licensing deal - BioXconomy
Cwm LLC Boosts Holdings in AbbVie Inc. $ABBV - MarketBeat
Diversified Management Inc. Takes Position in AbbVie Inc. $ABBV - MarketBeat
Adelphi Trust Co Makes New Investment in AbbVie Inc. $ABBV - MarketBeat
Operating expenses (excl. COGS) of AbbVie, Inc. – BSESOF:4AB - TradingView — Track All Markets
Fidelity SAI U.S. Quality Index Fund's AbbVie Inc(ABBV) Holding History - GuruFocus
Evercore ISI Tweaks AbbVie (ABBV) Estimates, Lowers Price Target Marginally - Yahoo Finance
Spectrum Asset Management Reduces AbbVie Stake - National Today
NSCLC Market: High-Growth Opportunities for Investors to 2034 – DelveInsight | AbbVie, AstraZeneca and Daiichi Sankyo, Shanghai Henlius Biotech, Moderna Therapeutics/ Merck, BeyondSpring, Cullinan - Barchart.com
Morgan Stanley Maintains AbbVie(ABBV.US) With Buy Rating, Maintains Target Price $270 - Moomoo
RemeGen (09995.HK) Receives USD650M Upfront Payment from AbbVie for RC148 - AASTOCKS.com
AbbVie Inc. $ABBV Shares Purchased by Farther Finance Advisors LLC - MarketBeat
애브비 (ABBV) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.01%
자본화:
|
볼륨(24시간):